Aprazer Healthcare Launched Sofokast Plus

Posted by

Aprazer Healthcare

September 4, 2025

On December 4, 2019

Aprazer Healthcare Launched under its brand Sofokast Plus, the generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg Tablet, for the treatment of patients with chronic hepatitis C virus (HCV) infection.

Newer

Aprazer Healthcare Launched HEPAKAST

Older Aprazer tie-up with BDR International

Disclaimer: This medical information is intended only for healthcare professionals in India. The products discussed herein may have different product labeling in other countries. The information within this site is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. For full Prescribing Information including indications, contraindications, warnings, precautions, and adverse events, please submit a medical information request. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Any liability for patent infringement is at the buyer's risk. The website does not sell/purchase any medicine.